Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

June 30, 2015

Conditions

Raynaud's Phenomenon Secondary to Systemic Sclerosis

Interventions

DRUG

Selexipag

Film-coated tablets containing 200 μg of selexipag to be administered orally twice daily

DRUG

Placebo

Placebo matching selexipag 200 μg tablets to be administered orally twice daily